Skip to content

Author

Andrew J. Schwab

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jan 2026

Serum Metabolomic Profiling Reveals Potential Mechanisms and Biomarkers of Seladelpar Treatment in Patients With Primary Biliary Cholangitis

Background Seladelpar, a potent and selective peroxisome proliferator‐activated receptor‐δ (PPARδ) agonist, is an approved second‐line therapy for primary biliary cholangitis (PBC) in patients with an inadequate response or intolerance to ursodeoxycholic acid (UDCA). In clinical studies, seladelpar significantly improv...

Yun-Jung Choi, Andrew J. Schwab, James Lim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.